Download the support programme guide
This page is intended for UK members of the public. If you are a healthcare professional please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Side-effects reporting information can be found in the footer of this page.
This page is intended for UK patients who have been prescribed iptacopan for paroxysmal nocturnal haemoglobinuria.
The information on this website does not replace the patient information leaflet which comes with your medication. Please always refer to your patient information leaflet for more information. If you have any questions, ask your doctor or care team. Connected – Stronger Together is a patient support programme organised and funded by Novartis.
Starting a treatment for PNH, whether it’s your first treatment or you’re switching from another therapy, can cause mixed feelings. This could be over potential uncertainty in knowing exactly what you expect with any treatment that’s new to your regimen. It is important to remember that however you feel, support is available for you at every step.
This website is designed to provide information and resources to help ensure you have a smooth experience with your treatment.
It provides you with important information about FABHALTA®▼ (iptacopan), and the available resources, including:
You’ve been prescribed FABHALTA®, also known as iptacopan, as you’ve been diagnosed with PNH with haemolytic anaemia (low levels of red blood cells) due to the breakdown of your red blood cells.1
Here, you can learn more and find out how you can get the most out of your prescribed treatment:
Dosing
How to get started with iptacopan
Possible side effects
Regular monitoring of your PNH symptoms
Risks and symptoms of serious infection
Tips for getting the most out of your treatment
Looking after your physical and emotional health is key to managing PNH. In this section, you can get tips on how to manage your symptoms, as well as information on maintaining good emotional and physical health.
In this section, you can learn more about PNH – what causes it, and a step-by-step overview of what happens in the body. You’ll also learn about the key signs and symptoms of the disease, including haemolysis.
Living with PNH can have its challenges. The Connected – Stronger Together Support Programme provides personalised support designed to help better manage your treatment and PNH. Find out more about this resource and the support services offered.
Here you can download tools that can help you manage your treatment and condition, as well as find answers to some of the questions you may have about iptacopan or PNH. There is also information on local support groups and useful websites.
Reference
FABHALTA® Package Leaflet – Information for the patient.
UK | November 2024 | FA-11228106
Reporting side-effects
If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. ▼ The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side-effects you may get. Please see www.mhra.gov.uk/yellowcard. for instructions on how to report side-effects.
Reporting side-effects
If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side-effects you can help provide more information on the safety of your medication.